Phase-I/II trial of Velcade (bortezomib) in combination with mitoxantrone and etoposide for relapsed or refractory acute leukemias.

Trial Profile

Phase-I/II trial of Velcade (bortezomib) in combination with mitoxantrone and etoposide for relapsed or refractory acute leukemias.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cytarabine; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jan 2015 Status changed from active, no longer recruiting to completed.
    • 07 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 07 Jan 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top